private investors based in Belgium had together acquired an 8% stake in
the Company. This stake was purchased from Biggar Limited, a charitable
foundation that is ThromboGenics' largest single shareholder. Biggar
now holds a 9.8% stake in ThromboGenics, and has informed the Company
that it intends to remain an important shareholder in ThromboGenics for
the long term.
- ThromboGenics shares entered the Bel Mid Index on 1 October
2008, following the quarterly review of the Belgian indices by
Euronext. The elevation of ThromboGenics to the Bel Mid Index reflects
the significant progress that the Company has made since its IPO in
- On 1 September, Patrik De Haes, MD, formerly the Company's
Chief Operating Officer, was appointed to succeed Professor Desire
Collen as the Company's new Chief Executive Officer. Dr. De Haes will
be proposed to become a member of the Board of Directors of
ThromboGenics at the next General Meeting. In the meantime, he will be
invited to participate in Board meetings.
ThromboGenics will continue to benefit from Professor Collen's significant scientific and drug discovery knowledge. Professor Collen will remain Chairman of ThromboGenics' Board of Directors.
Microplasmin in Eye Disease
ThromboGenics is working to finalise its Phase III clinical trial
program for microplasmin in the treatment of back of the eye disease,
following a successful End of Phase II meeting with the FDA. The initial
indication planned for the program is the nonsurgical resolution of
vitreomacular adhesion. Two placebo controlled trials are planned, one in
the U.S. and one combined European and North American trial. Together it is
anticipated that the two trials will recruit a total of approximately 640
patients, with the first trial ex
|SOURCE ThromboGenics NV|
Copyright©2008 PR Newswire.
All rights reserved